Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Phase 1
20 Years
74 Years
20 Years
74 Years
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Inclusion Criteria:
- Malignant solid tumor progressed, or no standard treatment available
- Tumor expression of Lewis Y antigen
Exclusion Criteria:
- Cancer therapy within 28 days before enrollment
- Pregnant or breastfeeding women
- Unstable or serious concurrent medical conditions
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Dose Limiting Toxicity, Adverse Event
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Wyeth is now a wholly owned subsidiary of Pfizer
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
3152K1-101
NCT ID:
NCT00257881
Start Date:
November 2005
Completion Date:
December 2006
Related Keywords:
- Neoplasms
- Tumor
- Neoplasms
Name | Location |
|---|
